--- title: "International Biotechnology (LON:IBT) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?" type: "News" locale: "en" url: "https://longbridge.com/en/news/279549208.md" description: "International Biotechnology (LON:IBT) shares have crossed above their 200-day moving average, trading at GBX 895.01 with a market cap of £285.54 million. The stock has a P/E ratio of -272.04 and a beta of 0.43. Analysts currently hold a 'Hold' rating on the stock, but it is not recommended as a top buy compared to five other stocks identified by top-rated analysts." datetime: "2026-03-18T07:16:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279549208.md) - [en](https://longbridge.com/en/news/279549208.md) - [zh-HK](https://longbridge.com/zh-HK/news/279549208.md) --- # International Biotechnology (LON:IBT) Stock Price Crosses Above 200-Day Moving Average - Time to Sell? International Biotechnology (LON:IBT - Get Free Report) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 878.44 and traded as high as GBX 908. International Biotechnology shares last traded at GBX 895.01, with a volume of 42,241 shares. ## International Biotechnology Stock Performance The stock has a market cap of £285.54 million, a P/E ratio of -272.04 and a beta of 0.43. The firm has a 50-day moving average price of GBX 931.64 and a 200-day moving average price of GBX 878.44. ## About International Biotechnology (Get Free Report) The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. ## See Also - Five stocks we like better than International Biotechnology _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in International Biotechnology Right Now? Before you consider International Biotechnology, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and International Biotechnology wasn't on the list. While International Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [UNBX.US](https://longbridge.com/en/quote/UNBX.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [NNNN.US](https://longbridge.com/en/quote/NNNN.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md) - [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md) - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md) - [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)